博瑞医药(688166) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥248,959,843.43, a decrease of 26.81% compared to ¥340,133,145.78 in the same period last year[4] - Net profit attributable to shareholders was ¥12,959,776.09, down 79.77% from ¥64,069,918.71 year-on-year[4] - Basic and diluted earnings per share were both ¥0.03, down 80.00% from ¥0.15 in the same period last year[4] - The net profit attributable to shareholders for Q1 2025 was RMB 12.96 million, a significant decline of 79.77% year-on-year[12] - Net profit for Q1 2025 was a loss of CNY 4,656,771.18, compared to a profit of CNY 61,809,832.36 in Q1 2024[25] - The total comprehensive income attributable to the parent company was CNY 12,889,554.95, a significant decrease from CNY 61,784,796.23 in the previous period[26] - The company reported a total comprehensive income loss attributable to minority shareholders of CNY -17,616,547.27 in the current period[26] Research and Development - R&D investment totaled ¥230,975,691.95, representing a significant increase of 255.09% compared to ¥65,047,828.56 in the previous year[4] - R&D expenses accounted for 92.78% of operating revenue, an increase of 73.66 percentage points from 19.12% in the same period last year[4] - The company is advancing its innovative drug BGM0504 for diabetes treatment and weight loss, currently in Phase III clinical trials in China[13] - The company submitted 7 domestic patent applications and received 2 domestic patent grants in Q1 2025, totaling 522 patent applications to date[18] - The company reported a 97.67% decrease in technical revenue to RMB 373,500 due to strategic adjustments in R&D resource allocation[12] - Research and development expenses for Q1 2025 were CNY 61,638,706.67, down from CNY 65,047,828.56 in Q1 2024[25] Assets and Equity - The company's total assets at the end of the reporting period were ¥5,285,273,296.81, reflecting a 2.34% increase from ¥5,164,346,157.48 at the end of the previous year[5] - The equity attributable to shareholders increased by 4.47% to ¥2,501,618,781.22 from ¥2,394,647,560.62 at the end of the last year[5] - The company's total equity increased to CNY 2,616,016,853.97 from CNY 2,437,375,863.13, a growth of 7.36%[23] Cash Flow and Financing - The net cash flow from operating activities was ¥106,992,992.51, a decrease of 27.93% compared to ¥148,461,770.92 in the previous year[4] - As of March 31, 2025, cash and cash equivalents amounted to RMB 812.68 million, an increase from RMB 765.35 million at the end of 2024[20] - The company reported a net cash outflow from investing activities of CNY -227,297,614.99 in Q1 2025, compared to CNY -138,378,675.23 in Q1 2024[28] - The company raised CNY 181,800,000.00 from minority shareholders in Q1 2025, contributing to a total financing cash inflow of CNY 518,151,900.00[28] - The total cash outflow from financing activities was CNY 348,760,914.55, compared to CNY 273,917,979.83 in the previous period[30] Sales and Revenue Breakdown - Product sales revenue for Q1 2025 was RMB 223.84 million, down 26.26% compared to the same period last year; antiviral product revenue decreased by 70.08%[11] - Total revenue for Q1 2025 was CNY 248,959,843.43, a decrease of 26.67% compared to CNY 340,133,145.78 in Q1 2024[24] - Total operating costs for Q1 2025 were CNY 266,560,026.02, slightly down from CNY 267,341,183.31 in Q1 2024[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,644[9]